Taysha Gene Therapies Inc (TSHA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Taysha Gene Therapies Inc (TSHA) has a cash flow conversion efficiency ratio of -0.193x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-40.88 Million) by net assets ($211.94 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See shareholders equity of Taysha Gene Therapies Inc for net asset value and shareholders' equity analysis.
Taysha Gene Therapies Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Taysha Gene Therapies Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Taysha Gene Therapies Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Taysha Gene Therapies Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Evergreen New Material Technology Inc. Co. A
SHG:603125
|
N/A |
|
PC Connection Inc
NASDAQ:CNXN
|
0.015x |
|
Jiangsu Provincial Agricultural Reclamation and Development Co Ltd
SHG:601952
|
0.011x |
|
Medicover AB (publ)
ST:MCOV-B
|
0.170x |
|
RAPT Therapeutics Inc
NASDAQ:RAPT
|
-0.082x |
|
Greatech Technology Bhd
KLSE:0208
|
0.011x |
|
Okeanis Eco Tankers Corp.
NYSE:ECO
|
0.069x |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA
|
0.056x |
Annual Cash Flow Conversion Efficiency for Taysha Gene Therapies Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Taysha Gene Therapies Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see TSHA market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $246.94 Million | $-93.09 Million | -0.377x | +66.80% |
| 2024-12-31 | $71.53 Million | $-81.22 Million | -1.136x | -16.55% |
| 2023-12-31 | $74.94 Million | $-73.02 Million | -0.974x | +98.95% |
| 2022-12-31 | $949.00K | $-88.39 Million | -93.140x | -7490.43% |
| 2021-12-31 | $95.38 Million | $-117.04 Million | -1.227x | -903.50% |
| 2020-12-31 | $251.30 Million | $-30.73 Million | -0.122x | +87.77% |
| 2019-12-31 | $-135.00K | $135.00K | -1.000x | -- |
About Taysha Gene Therapies Inc
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 … Read more